Members of the RAS family of GTPases (KRAS4A, KRAS4B, HRAS, and NRAS) are the most frequently mutated oncogenes in human cancers. The CAAX motif in the Cterminal hypervariable region (HVR-CAAX domain) contains the cysteine residue that is critical for protein prenylation that enables RAS protein membrane localization, homodimer/oligomer formation, and activation of effector signaling and oncogenic activity. However, it remains unclear if RAS can interact with other prenylated proteins, and if so, how this impacts RAS function. Here we use a newly developed quantifiable Recombinase enhanced Bimolecular Luciferase Complementation strategy (ReBiL2.0)
Results and Discussion
We developed ReBiL as a platform to analyze transient and low-affinity proteinprotein interactions (PPIs) in living cells [1] . ReBiL signals depend on both the binding affinity of the interacting proteins and the levels at which they are expressed. Thus, high expression levels of low-affinity PPI's and low expression levels of high affinity PPI's could generate similar luminescent signals ( Fig. 1a ). Although controlled by the same TRE bi-directional promoter, split-luciferase (½luc) fusion-proteins are not always expressed in a 1:1 stoichiometric ratio. These issues can complicate data interpretations. We modified the available ReBiL system (referred to below as ReBiL2.0) to enable precise quantification and comparison of ReBiL luminescent results obtained with different PPI pairs from different ReBiL reporter cells. We normalize luminescent signal with the amount of expressed ½luc fusion protein (explained in detail in Fig. 1 and Methods). We incorporate a single copy of an HA-epitope tag in the linker region of each ½luc fusion protein to enable accurate determination of their expression ratio using a single anti-HA antibody and quantitative western blotting (Fig. 1b) . Importantly, as the ReBiL platform is doxycycline inducible, conditions can be established to express ½luc fusion proteins at near-endogenous levels. The ReBiL2.0 system provides a quantitative strategy to significantly enhance the accuracy required to map PPI networks in living cells.
C-terminal HVR-CAAX domain prenylation is required for RAS membrane localization and homodimer or nanocluster formation [2] . Importantly, the prenylated protein database predicts more than 200 prenylated human proteins [3] , raising the possibility that RAS proteins might interact with some of them. We used ReBiL2.0 to investigate if KRAS4B (referred to as KRAS unless stated otherwise) can colocalize or co-cluster with other prenylated proteins in living cells, and we then investigated the impact of such colocalization on downstream signaling in the MAPK pathway. To validate this assay, we first asked if KRAS homo-oligomers or nanoclusters are generated in engineered KRAS ReBiL cells (Fig 2a) . We appended N-terminal split luciferase (nl) and C-terminal split luciferase (cl) [1] to the N-terminus of KRAS (designated nl-KRAS and cl-KRAS respectively, Fig 2a) . This fusion configuration maintains the intact C-terminal HVR-CAAX domain required for KRAS prenylation.
These fusions did not affect KRAS activity as determined by NIH3T3 growth assays ( Fig. 2b) . When expressed at physiologically relevant levels ( Fig. 2c ), nl-KRAS and cl-KRAS generated robust luminescent signals (Fig. 2d ). Since reconstitution of a functional split luciferase requires a minimum 1:1 ratio of nl-KRAS and cl-KRAS, we interpret these results to indicate that KRAS can form at least homodimers, which is consistent with prior observations [4] . However, formation of KRAS oligomers or nanoclusters [5] cannot be excluded.
We next determined if KRAS activation or effector interaction are required for dimer/oligomer (hereafter referred to as multimer) formation. KRAS_G12D and KRAS_S17N mutants interact with wild type KRAS_WT (Fig. 2d) , indicating that the GTP-bound active form (represented by the KRAS_G12D mutant) and GDP-bound inactive form (represented by the KRAS_S17N mutant) have no impact on multimer formation. In addition, the effector binding mutant KRAS_Y40C [6] interacts well with KRAS_WT, indicating that Raf effector binding is dispensable for KRAS multimer formation [4] . Although Tyr64 has been reported to be critical for HRAS dimerization in artificial membranes [7] , we observed no measurable effect of a Y64A mutation on KRAS dimer formation in living cells (Fig 2d) [4] even though HRAS and KRAS share over 90% sequence identity in the G-domain [2] including Tyr64. Taken together, these data are consistent with previous results showing that the G-domain plays a minimal role in KRAS dimer/oligomer formation, and they validate the use of ReBiL to investigate Ras homo-and heteromeric interactions.
Previous studies showed that a single Cys to Ser mutation (KRAS_C185S) in the CAAX motif farnesylation site both abolishes RAS protein membrane association [8] and inactivates downstream signaling [4] . Indeed, the farnesyltransferase (FTase) inhibitor FTI-2153 [9] dose-dependently reduced the luminescent signal generated by nl-KRAS/cl-KRAS complementation ( Fig. 2e ). As FTI treatment affected neither the luminescence generated by BRCA1-BARD1 RING-domain [1] , nor viability ( Fig. 2e ), we conclude that the ability of the inhibitor to reduce the luminescent signal from nl-KRAS/cl-KRAS complementation is not due to an indirect effect of FTI-2153, but rather to its ability to inhibit farnesyltransferase and to subsequently block KRAS farnesylation and membrane localization. This is a surprising result because it has been shown that KRAS can be prenylated by geranylgeranyltransferase I (GGTase I) when FTase is inhibited by FTI in cells that overexpress pMEV [10, 11] , a mutant transporter protein that facilitates mevalonate uptake [12] . This alternative prenylation restores KRAS membrane localization and function that results in resistance of FTI inhibition [2] .
However, the alternative prenylation process might not be efficient in U2OS cells as treatment of U2OS with an FTI has previously been reported to prevent KRAS prenylation [13] . Thus, we interpret our results to indicate that the FTI mediated reduction in nl-KRAS/cl-KRAS association derives from its ability to prevent KRAS membrane association. These results suggest that in addition to HRAS mutant cancers, FTI could have beneficial effects in those KRAS mutant cancers where GGTase I does not contribute significantly to KRAS modification in the context of FTI treatment. While drugging of mutant RAS in cancers has been largely unsuccessful [14] , we suggest that the KRAS ReBiL strategy could provide a rapid, high throughput platform for identifying therapeutics that inhibit RAS membrane localization, multimerization, and activity in specific cancers.
As expected, a single cysteine mutation in nl-KRAS_C185S abolishes luciferase complementation ( Fig. 3b ), consistent with the notion that HVR-CAAX farnesylation is critical for KRAS membrane localization and multimer formation [4] . We next determined if CAAX domains from HRAS and NRAS enable heteromer formation with KRAS. To focus on the HVR-CAAX domain, we replaced the G-domains of each RAS isoform with the monomeric blue fluorescent protein mTagBFP (tBFP) [15] . The ½luc and tBFP fusions are designated nl-tBFP-HVR-CAAXH, nl-tBFP-HVR-CAAXN, and nl-tBFP-HVR-CAAXK to indicate the origins of HVR-CAAX domains from H, N and KRAS, respectively ( Fig. 3a) . The nl-tBFP-HVR-CAAXN, and nl-tBFP-HVR-CAAXK efficiently reconstituted luciferase activity efficiently when paired with cl-KRAS ( Fig. 3b ), indicating that KRAS forms heteromers with NRAS in a G-domain independent fashion. By contrast, we consistently observed that nl-tBFP-HVR-CAAXH and cl-KRAS interact less efficiently than nl-KRAS/cl-KRAS and nl-tBFP-HVR-CAAXK/cl-KRAS pairs (Fig. 3b ). This indicates that HRAS has a lower probability of interacting with KRAS, which is consistent with a previous study showing that KRAS and HRAS can be co-clustered through lipid-mediated spatial cross talk [5] . Consistent with a previous study [4] , the CAAX domain itself appears to be sufficient for driving proximal membrane localization since appending only nl and cl to the HVR-CAAXK (nl-HVR-CAAXK and cl-HVR-CAAXK) enabled efficient complementation, while nl/cl alone and cl-KRAS/nl-tBFP (without HVR-CAAX) exhibited negligible luminescent signals (Fig. 3b ). Thus, we refer to these Gdomain independent, but HVR-CAAX dependent, interactions as "proximity enabled" or "proximal" interactions or protein "co-clusters". We use the latter term as physical measurements suggest that RAS can localize in the membrane as multimeric structures [5] . Importantly, the KRAS proximal interactions are not significantly influenced by complementation of the two ½luc moieties alone, as the C185S mutant did not generate an appreciable luminescent signal (Fig 3b) .
The above results establish the ability of the ReBiL2.0 assay to capture interactions between prenylated proteins located in membrane domains that coincide with or overlap those occupied by KRAS. Interestingly, KRAS4A, which has a different HVR-CAAX domain [16] than the KRAS4B splice variant, produced a significant ReBiL signal with KRAS4B (Fig 4a) , implying that KRAS4A and KRAS4B reside in overlapping membrane domains. These results suggest that KRAS4A and 4B might exhibit functional similarities that could impact each other's downstream effects [16] .
These observations led us to wonder whether other prenylated proteins are sufficiently near the membrane domains in which KRAS resides to enable heteromeric interactions. As a specificity control, Fig. 4b shows that KRAS does not interact with RheB, a prenylated protein localized to endomembranes [17] , not the plasma membrane in which RAS proteins reside. KRAS also does not interact with Rnd3 ( Fig.  4b ), which also localized to the plasma membrane [17] . This suggests that they reside in sufficiently different plasma membrane domains as to preclude interaction. In contrast, we discovered that KRAS does interact with the genetically defined KRAS suppressor DIRAS3 ( Fig. 4b , and Sutton et al, in revision), RAC1 and RAC2 (Fig. 4c ) in a prenylation-dependent fashion since a Cys to Ser mutation in the CAAX motif of each protein abolishes luciferase complementation (Fig. 4b, c ). The functional importance of such interactions is indicated by DIRAS3, which is a tumor suppressor that downregulates MAPK activity [18] by a mechanism facilitated by its membrane colocalization with RAS proteins (Sutton et al, in revision).
Chemically-induced KRAS_G12D homodimerization can activate the MAPK pathway [4] . Consistent with this, we observed that doxycycline-induced expression of nl-KRAS_G12D and cl-KRAS_G12D also activates the MAPK pathway as indicated by increased phosphorylation of AKT and ERK1/2 ( Fig. 5a , b) in ReBiL cells. However, we wondered about the extent to which association between the ½luc moieties could contribute to protein interactions in general, and to MAPK signaling via the RAS pathway in specific. First, we did not detect ½luc (nl/cl) complementation in the absence of the RAS HVR-CAAX domain (Fig. 3b ). Second, we previously showed that preformed p53-Mdm2 complexes (p53-Mdm2 Kd = 600 ~ 420 nM [19]) appended with split luciferase complementing pairs can be readily and dose dependently disrupted by the small molecule Nutlin-3a [1] . This indicates that 1/2luc association using the constructs employed in the ReBiL system must contribute little to protein-protein interactions in this system. By contrast, Nutlin-3a did not disrupt p53-Mdm2 complexes when each protein was fused to split NanoLuc [20] . These data reveal that complexes formed with split NanoLuc molecules are very stable, as has been observed with split green fluorescent protein (GFP) complementation (dissociation rate estimated as ~ 9.8 years [21]). Third, we previously showed that the ReBiL assay successfully detects the weak and transient interactions between the E3 ubiquitin ligase FANCL and Ube2t, its cognate E2 ubiquitin conjugating enzyme. By contrast, only background luminescent signal was detected when assaying interaction between a FANCL RING domain mutation (FANCL_C307A) and Ube2t [1] . These results indicate that the affinity between the two ½luc moieties must be smaller than that of FANCL-Ube2t. Together, these data are consistent with the two firefly ½luc moieties having very low affinity for each other.
While the contribution to protein association is likely negligible, it must be nonzero as the ½luc moieties must associate to some degree to reconstitute, if transiently, We next determined whether proximal interactions between KRAS and a nonfunctional partner could attenuate its activity. To this end, we used the cl-tBFP-HVR-CAAXK because it colocalizes with KRAS but lacks a functional G-domain. The cl-tBFP-HVR-CAAXK reduces both phospho-AKT and phospho-ERK1/2 signals in the presence of serum starvation and EGF stimulation ( Fig. 5c, d) . These results indicate that KRAS activity can be impacted by proximal interactions with heterologous proteins even if they lack appreciable interaction affinity. Similar results were also observed when the cLuc (cl) was removed from cl-tBFP-HVR-CAAXK ( Fig. 5c, d) , indicating that the observed effect did not derive from low affinity ½luc interactions. These data are consistent with prior reports that a wild-type RAS allele acts as a suppressor of mutant RAS in murine model studies [23] [24] [25] . We confirmed this finding in the ReBiL system ( Fig. 5e ), although the degree of inhibition was greater using tBFP than WT RAS. We reason that the cl-tBFP-HVR-CAAXK inhibits KRAS_G12D better than WT RAS ( Fig. 5c, d ) because it lacks a functional G-domain, enabling more significant interference with the function of the KRAS mutant and an inability to be cross-activated through KRAS_G12D-mediated recruitment of a guanine nucleotide exchange factor (e.g. SOS1) [26] . Taken together, our results suggest that KRAS signaling output can be fine-tuned by proximity mediated interaction of homologous or heterologous proteins.
RAS activity can be inhibited by the Ras binding domain (RBD; amino acid 51-220) of cRaf (or Raf1) [27] . Since the results presented above emphasize the importance of membrane mediated proximal interactions or co-clustering to regulate RAS activity, we hypothesize that targeting the RBD to the membrane should inhibit RAS more potently through a combination of proximity facilitated interaction or generation of RBD-RAS co-clusters added to the affinity of the RBD for RAS. To this end, we fused the HVR-CAAXK to the C-terminus of RBD. We added to the RBD a destabilizing domain (DD, i.e., FKBP12_F36V_L106P) to enable regulation of protein levels [28] (designated TRE-DD-RBD-CAAXK). As a negative control, we generated TRE-DD-RBD, which should not co-cluster with RAS ( Fig. 6a ). Both constructs were integrated as a single copy into the U2OS parental ReBiL cell line. While the small molecule ligand Shield1 was not effective in these DD-fused constructs (data not shown), the results clearly show that DD-RBD-CAAXK inhibited both Erk1/2 phosphorylation ( Fig. 6b ) and cell proliferation ( Fig. 6c ) far better than similar levels of DD-RBD. These results are reminiscent of an early study showing that despite high binding affinity (6.2 nM to RAS(GTPγS)), only a membrane associated intrabody (iDab#6-memb) exhibits significant inhibitory effects in vivo [29] . However, the importance of membrane co-clustering of Ras with the intrabody was not discussed in that study [29] .
In summary, our results reveal that the ReBiL2.0 assay accurately captures KRAS membrane spatial organizations studied by diverse methods including photoactivated localization microscopy (PALM) [4] , electron microscopy (EM) [30] and other imaging methods (reviewed in [5] ). Our results validate the ReBiL2.0 assay as a robust tool to study membrane-anchored proteins and their interactions, and to identify new interaction partners in living cells. Indeed, we discovered that KRAS4B can colocalize with KRAS4A as well as with a subset of small GTPase family proteins such as RAC1, RAC2, and DIRAS3. We demonstrate its use for studying structure-function requirements for such interactions, and for documenting the mechanisms by which 
METHODS

Construction of ReBiL targeting plasmids and cell lines. The methods for
constructing ReBiL plasmids and cell lines have been previously described [1] . ReBiL The denatured lysates were separated by 10% SDS-PAGE and transferred to PVDF membranes (Millipore No. IPFL00010) as described previously [1] . The PVDF membrane was then probed with the anti-HA and anti-Actin antibodies (see Supplemental Table 2) The G-domain of nl-HA-HRAS was replace with TagBFP (tBFP). The G-domain of nl-HA-NRAS was replace with tBFP. The G-domain of nl-HA-KRAS was replace with tBFP. This construct contains DD-RBD only. Fig. 6 .
Note: 1. KRAS4B is referred to as KRAS unless stated otherwise. 2. All ReBiL targeting plasmids listed here were resistant to ampicillin and their sequences were verified by Sanger sequencing. 3. All U2OS ReBiL cell lines listed here are resistant to G418 and Blasticidin.
